EC Number   |
Application |
Reference |
|---|
    3.6.1.5 | agriculture |
expression of enzyme in in Lotus japonicus results in enhanced nodulation that correlates with expression level |
670584 |
| 3.6.1.5 | analysis |
immune sera that recognize specifically the B domain of NTPDase 1 are produced against synthetic peptides (LbB1LJ and LbB2LJ) derived from this domain of NTPDase from Leishmania brasiliensis. The polyclonal antibodies have effective anti-leishmanial effect, reducing significantly in vitro promastigotes growth (21-25%), an antiproliferative effect is also demonstrated by immune sera produced against recombinant r-pot B domain, and two other synthetic peptides (potB1LJ and potB2LJ). In addition, using these biomolecules in ELISA technique, IgG1 and IgG2 subclasses reactivities of either healthy dogs or infected by Leishmania infantum and classified clinically as asymptomatic, oligosymptomatic and symptomatic are tested. Analysis of distinct IgG1 and IgG2 seropositivities patterns suggest antibody subclasses binding epitopes along B domain for protection against infection, indicating this domain as a tool for prophylactic and immunotherapeutic investigations |
-, 758530 |
| 3.6.1.5 | analysis |
usage of the enzyme in a two-dimensional array ATP/ADP sensitive image sensor, with a uniform distribution of chemically immobilized apyrase (via two different methods (3-APTES and CEST)). The enzyme sensor changes ATP into AMP, and the concentration of ATP reduces with time. The time-dependent profile of the potential response is different from the common ion sensor on which the concentration of the analyte ion is constant at an equilibrium state. Two ways of the measurement are used: 1. the addition measurement and 2. the steady measurement, overview |
756325 |
| 3.6.1.5 | drug development |
Ecto-NTPDase1 is a target candidate in chemotherapy of Chagas disease |
700876 |
| 3.6.1.5 | drug development |
the NTPDase isozymes are targets for development of potent and selective drug-like NTPDase inhibitors |
755781 |
| 3.6.1.5 | medicine |
activation of CD39 has potential for treating inflammatory diseases, while inhibition is suggested as a strategy for the immunotherapy of cancer |
755782 |
| 3.6.1.5 | medicine |
augmenting CD39 activity is a potential therapy to improve both short- and long-term outcomes of ischemia-reperfusion injury (IRI) by reducing the extracellular concentration of proinflammatory ATP and promoting adenosine generation. In mouse models of IRI, treatment with soluble CD39 (apyrase) or expression of a human CD39 (hCD39) transgene in mice (CD39Tg mice) reduce the severity of acute kidney injury (AKI) as evidenced by decreased serum creatinine and reduced tubular injury score at 24 hours |
758513 |
| 3.6.1.5 | medicine |
enzyme in lipid vesicles effectively inhibits platelet aggregation when activated by ADP, collagen, or thrombin, and also promotes platelet disaggregation. Treatment with enzyme lipid vesicles preserves platelet counts after thromboplastin injection |
670068 |
| 3.6.1.5 | medicine |
enzyme inhibits ADP- collagen- and thrombin-induced human platelet aggregation in dose-dependent manner, use as a therapeutic agent for inhibition of platelet-mediated thrombosis |
670643 |
| 3.6.1.5 | medicine |
its unique enzymatic activity makes the salivary apyrase an attractive candidate as a therapeutic agent for the treatment of thrombotic pathologies |
712658 |
